

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.
樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

**POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL
MEETING HELD ON DECEMBER 18, 2025**

References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the 2025 second extraordinary general meeting (the “**Second 2025 EGM**”) of the Company both dated November 28, 2025. Capitalised terms used herein shall have the same meanings as those defined in the Notice and the Circular unless the context requires otherwise.

ATTENDANCE AT THE SECOND 2025 EGM

The Second 2025 EGM was chaired by Dr. Pu Zhongjie, the chairman of the Board and an executive Director, and was successfully held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, the PRC on Thursday, December 18, 2025 at 10:30 a.m. The Second 2025 EGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results of the Second 2025 EGM are lawful and valid.

The Board is pleased to announce that all the resolutions proposed at the Second 2025 EGM as set out in the Notice were duly passed by the Shareholders by way of poll at the Second 2025 EGM.

POLL RESULTS OF THE SECOND 2025 EGM

The poll results in respect of all the resolutions proposed at the Second 2025 EGM are as follows:

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
1.	Subject to and conditional upon the Listing Committee of the Stock Exchange granting approval for the listing of, and permission to deal in, the new Shares to be allotted and issued underlying the share awards granted in accordance with the terms and conditions of the Restricted Share Unit Scheme of the Company (the “ RSU Scheme ”), the RSU Scheme be and is hereby approved and adopted, and any Director be and is hereby authorised to do all such acts and to enter into all such transactions, arrangements and agreements as he may in his absolute discretion consider necessary or expedient in order to give effect to the RSU Scheme.	1,032,176,764 (98.180965%)	19,120,519 (1.818750%)	3,000 (0.000285%)
2.	Subject to and conditional upon the passing of resolutions numbered 1, the Scheme Mandate Limit (as defined in the RSU Scheme) on the total number of Shares which may be issued in respect of all awards involving issue of new Shares that may be granted under the RSU Scheme and any other share scheme(s) of the Company, representing 5% of the total number of Shares in issue (excluding Treasury Shares, if any) at the date of the passing of this resolution, be and is hereby approved and adopted and any Director be and is hereby authorized to take all such steps and attend all such matters, approve and execute (whether under hand or under seal) such documents and do such other things, for and on behalf of the Company, as he may in his absolute discretion consider necessary, desirable or expedient to effect and implement the Scheme Mandate Limit.	1,032,031,764 (98.167173%)	19,265,519 (1.832542%)	3,000 (0.000285%)
3.	Subject to and conditional upon the passing of resolutions numbered 1 and 2, any Director be and is authorised to make any necessary amendments to the Articles of Association of the Company to reflect the change to the total number of issued shares of the Company due to the issue of new shares of the Company pursuant to the RSU Scheme, and such Director be and is hereby authorised to do such other things, for and on behalf of the Company, as he may in his absolute discretion consider necessary, desirable or expedient to effect the amendments to the Articles of Association of the Company, including but not limited to applying to the relevant regulatory authorities for the relevant approval, registration and filing procedures.	1,031,293,609 (98.096959%)	20,001,674 (1.902565%)	5,000 (0.000476%)

As more than two-thirds of the votes were cast in favour of the resolutions numbered 1 to 3 above, these resolutions were duly passed as special resolutions of the Company.

Notes:

1. As at the date of the Second 2025 EGM, the total number of issued ordinary Shares was 1,804,439,838 H Shares, which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the Second 2025 EGM.
2. There were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the Second 2025 EGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the Second 2025 EGM.
4. The total number of issued Shares held by the Shareholders in person or their proxies who have attended the Second 2025 EGM and are entitled to vote is 1,051,300,283 Shares, representing approximately 58.26% of the total number of issued Shares as at the date of the Second 2025 EGM.
5. The Company's H Shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the Second 2025 EGM for the purpose of vote-taking.
6. All Directors attended the Second 2025 EGM in person or via electronic means.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
December 18, 2025

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziye (chief executive officer) as executive Directors; Ms. Pu Jue and Ms. Qin Yiran as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.